Setmelanotide vs Cotadutide
Head-to-head comparison of Setmelanotide (Setmelanotide Acetate) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Setmelanotide | Cotadutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Setmelanotide Acetate | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | N/A | ~4,700 Da |
| Half-Life | Approximately 11-16 hours | Approximately 24 hours |
| Amino Acids | N/A | 37 |
| Typical Dose | 1-3 mg daily | 0.3-3 mg daily in clinical studies |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 80 | 18 |
| Research Status | Clinical | Clinical |
Setmelanotide Benefits
- ✓reduced hyperphagia
- ✓body-weight reduction
- ✓MC4R pathway activation
- ✓improved satiety signaling
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Setmelanotide Dosing
1 mg SC daily|titrate weekly to 2-3 mg/day|follow study or label-based escalation
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Setmelanotide Side Effects
- ⚠hyperpigmentation
- ⚠nausea
- ⚠injection-site reactions
- ⚠fatigue
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Setmelanotide
Setmelanotide has shown clinically meaningful reductions in hunger and weight in POMC, PCSK1, and LEPR-related obesity. It is one of the most important mechanistic peptides for rare-disease obesity research.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.